Moonlitnight, Sorry to read of Don's advancement while on abiraterone. Even though there has been some recent evidence that suggests if aberaterone is not effective, then enzalutamide will also likely not be effective, there are so many PC variants, I would still give it a shot. I failed enzalutamide, but have no hesitation sometime in the future giving aberaterone a shot at it. The two do have different mechanisms of action, so I would think that in some cases, one may work even if the other did not. I hope and pray that you will be able to report to us that Don is such a case.
When I went to see Myers after failing on the enzalutamide/prostvac trial, he was real encouraged with his patients responses to aberaterone and Xofigo . At that time, Myers was not much of a chemo advocate, and told me that only 5% of his patients required it. However, when he saw that I had new spots on my liver and adrenal gland, he was concerned that any further PC advancement there could be life threatening. He knew that I might not respond to aberaterone, and Xofigo would do nothing for the threatening soft lesions, so recommended my going forward with the chemo/xl184 trial.
I'm not going to try and sell you on chemo, and understand the hesitance, but if you and/or Don ever want to talk to me about
my experiences on Taxotere, please do reach out. Assuming Don's CT scans don't show anything of concern, and his advancement is mainly within his bones, Xofigo sure does seem like a great option for him, a long with the enzalutamide.
BTW, you probably already found this out; Xofigo was approved in Canada the end of 2013 Canada Approval
My best to you and Don,